Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss

Clinical trial NCT02132130 · COMPLETED

Trial details

NCT number: NCT02132130
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss

Start date: 2014-06-23
Primary completion: 2019-12-09
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.